NCT07506876

Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Legacy Health System · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery

Conditions

• Breast Cancer - Infiltrating Ductal Carcinoma
• HER-2 Positive Breast Cancer

Interventions

Type	Name	Description
DRUG	Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy	Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy

Timeline

• Start date: 2026-04-01
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2026-04-02
• Last updated: 2026-04-02

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study